Helix BioPharma Corp. has strengthened its leadership team with two key executive appointments designed to advance the company's oncology research and communication strategies. Veronika Kandziora joins as Chief Operating Officer, bringing over 20 years of leadership experience across biopharma, financial, and consulting sectors. Her appointment brings deep institutional knowledge to the role, having previously served as Corporate Secretary and strategic consultant to Helix. With a background in international finance and compliance, she is positioned to provide strategic alignment and operational strength to the organization. Her expertise spans complex international projects and includes advanced training in regulatory and governance environments.
Dr. Jessica Kourniaktis takes on the role of Director of Communications with a decade of experience in life sciences communication. Her background combines academic research with strategic communications, including founding a boutique consultancy and serving as an executive in multiple biopharma startups. She previously worked as a Board Member of ESGTI AG. Her communications approach is characterized by analytical depth and compelling storytelling, with a focus on articulating scientific ventures' visions effectively to stakeholders and the broader medical community.
CEO Thomas Mehrling emphasized the strategic importance of these appointments, noting that Kandziora's organizational leadership and Kourniaktis's strategy-first communications approach will be critical in advancing the company's mission of developing treatments for hard-to-treat cancers. These leadership changes signal Helix BioPharma's commitment to accelerating its oncology research and improving communication about its innovative approaches to cancer treatment. The appointments reflect a strategic effort to strengthen the company's operational capabilities and public engagement in the complex and competitive field of oncological drug development.
Helix BioPharma's pipeline is centered on a proprietary technology platform targeting CEACAM6-expressing solid tumors. The company's lead candidate, Tumour Defence Breaker™ L-DOS47, is a clinical-stage antibody-enzyme conjugate designed to neutralize tumor microenvironments and enhance anti-cancer immunity. These leadership appointments are expected to provide the operational excellence and communication clarity needed to advance these promising oncology treatments through clinical development and regulatory processes. The strengthened leadership team positions Helix BioPharma to more effectively navigate the challenges of oncology drug development while maintaining clear communication with investors, regulatory bodies, and the medical community about their progress and scientific approach.
